報價延遲最少15分鐘:2026/04/21 23:57 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.87 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.85/-0.61
|
|
企業價值
317.97M
|
| 資產負債 |
|
每股賬面淨值
9.07
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
19.09M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. |
